France · Delayed Price · Currency is EUR Neovacs Statistics
Total Valuation
Neovacs has a market cap or net worth of EUR 300,631. The enterprise value is 432,780.
| Market Cap | 300,631 |
| Enterprise Value | 432,780 |
Important Dates
The next estimated earnings date is Tuesday, September 15, 2026.
| Earnings Date | Sep 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neovacs has 159,064 shares outstanding.
| Current Share Class | 159,064 |
| Shares Outstanding | 159,064 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.51 |
| PB Ratio | 0.02 |
| P/TBV Ratio | 0.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.67, with a Debt / Equity ratio of 0.01.
| Current Ratio | 0.67 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -8.71 |
Financial Efficiency
Return on equity (ROE) is -23.23% and return on invested capital (ROIC) is -18.70%.
| Return on Equity (ROE) | -23.23% |
| Return on Assets (ROA) | -10.66% |
| Return on Invested Capital (ROIC) | -18.70% |
| Return on Capital Employed (ROCE) | -29.97% |
| Weighted Average Cost of Capital (WACC) | 274.69% |
| Revenue Per Employee | 12,454 |
| Profits Per Employee | -272,371 |
| Employee Count | 16 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.99% in the last 52 weeks. The beta is 46.19, so Neovacs's price volatility has been higher than the market average.
| Beta (5Y) | 46.19 |
| 52-Week Price Change | -99.99% |
| 50-Day Moving Average | 2.44 |
| 200-Day Moving Average | 403.73 |
| Relative Strength Index (RSI) | 40.99 |
| Average Volume (20 Days) | 2,230 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Neovacs had revenue of EUR 199,267 and -4.36 million in losses.
| Revenue | 199,267 |
| Gross Profit | -2.91M |
| Operating Income | -5.71M |
| Pretax Income | -5.46M |
| Net Income | -4.36M |
| EBITDA | -5.52M |
| EBIT | -5.71M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 38,511 in cash and 170,663 in debt, with a net cash position of -132,152 or -0.83 per share.
| Cash & Cash Equivalents | 38,511 |
| Total Debt | 170,663 |
| Net Cash | -132,152 |
| Net Cash Per Share | -0.83 |
| Equity (Book Value) | 18.89M |
| Book Value Per Share | n/a |
| Working Capital | -1.31M |
Cash Flow
In the last 12 months, operating cash flow was -3.09 million and capital expenditures -16,275, giving a free cash flow of -3.11 million.
| Operating Cash Flow | -3.09M |
| Capital Expenditures | -16,275 |
| Depreciation & Amortization | 190,459 |
| Net Borrowing | -233,227 |
| Free Cash Flow | -3.11M |
| FCF Per Share | -19.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,866.37% |
| Pretax Margin | -2,738.87% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neovacs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1,449.60% |
| FCF Yield | -1,034.90% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 23, 2026. It was a reverse split with a ratio of 0.0001.
| Last Split Date | Jun 23, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.0001 |
Scores
Neovacs has an Altman Z-Score of -4.47 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.47 |
| Piotroski F-Score | 2 |